MGX(MGX)
MGX
ANALYST COVERAGE5 analysts
BUY
▲ +962.3%upside to target
L $7.00
Med $14.50consensus
H $22.00Key MetricsTTM
Market Cap$51.39M
Revenue TTM$22.33M
Net Income TTM-$85.89M
Free Cash Flow-$87.54M
Gross Margin-12.5%
Operating Margin-415.5%
Net Margin-384.6%
Return on Equity-51.2%
Return on Assets-43.6%
Debt / Equity0.28
Current Ratio6.43
EPS TTM$-2.29
PRICE
Prev Close
1.31
Open
1.34
Day Range1.30 – 1.37
1.30
1.37
52W Range1.24 – 3.95
1.24
3.95
5% of range
VOLUME & SIZE
Avg Volume
209.9K
FUNDAMENTALS
P/E Ratio
-0.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
38
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30
MGX News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Matthew L. WeinGeneral Counsel, Compliance Officer, Head of BD&L and Corporate Secretary
Pamela WapnickChief Financial Officer
Alan BrooksSenior Vice President of Research
Brian Charles ThomasCo-Founder & Director
Jian IrishCEO, President & Director
Joseph KnowlesCo-Founder & Member of Scientific Advisory Board
Mark LeonardSenior Vice President of Technical Development & Operations
Katalin KauserSenior Vice President of Translational Biology